NCT05283694View on ClinicalTrials.gov

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

June 12, 2018

Study Completion Date

June 12, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

risankizumab

Subcutaneous Injection via prepared syringe

DRUG

risankizumab

Subcutaneous Injection via syringe pump

Trial Locations (1)

60030

Acpru /Id# 165737, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY